By The Gateway Pundit - Anthony Scott - December 19, 2022
Just weeks after Elon Musk, co-founder of Neuralink, announced that the company is just six months away from implanting brain-computer interfaces in humans, both Bill Gates and Jeff Bezos invested a hefty sum into Synchron, Inc., a brain computing interface company.
On Thursday, Syncron announced it has received $75 million from its latest round of funding.
A large amount of that $75 million stemmed from an investment by Bezos Expeditions.
Another chunk of the investment came from Gates Frontier which is an investment arm of Bill Gates alongside Microsoft.
Fortune reported these details about Synchron’s goal:
Synchron is focused on restoring some helpful capabilities to paralyzed patients, who can use its Synchron Switch, a brain computer interface (BCI), to move a computer cursor on a screen with just their thoughts. With a minimally-invasive procedure, the BCI is implanted in the blood vessel on the surface of the motor cortex of the brain via the jugular vein. Other companies, including Neuralink, use more invasive techniques that involve going through the skull.
On the surface, it appears Synchron’s goal is to help those disabled but as history teaches us, new technology is usually intercepted and used for war or nefarious plans.
Another reason brain-computer interfaces are a problem for humans is that they are susceptible to being hacked.
Just imagine if a high-profile human is hacked.
The damage that can be done by a human being controlled by an outside source is unimaginable.
Both Musk, Gates, and Bezos also have invested heavily in AI technology.
If you know anything about AI, then you know AI thrives by collecting data.
And what better way to collect data than by connecting technology to the human brain?
The thought that both the world’s richest man alongside the second richest one are both investing in brain interface technologies is quite concerning.
Gates, Bezos invest in Synchron’s brain-computer interface
Published Dec. 16, 2022By Peter Green, Senior Editor
- The investment arms of billionaires Jeff Bezos and Bill Gates joined a $75 million investment round in Synchron, a Brooklyn-based firm building a brain-computer interface for people who are paralyzed below the neck.
- The investment will fund clinical trials and further development of the device, which is inserted into the brain through the jugular vein, removing the need for invasive surgery.
- Synchron implanted its first BCI in a U.S. patient in July, while Twitter CEO Elon Musk’s BCI startup, Neuralink, said it expects to test its technology on humans by mid-2023.
Synchron’s “Switch” BCI is implanted in a blood vessel on the surface of the brain’s motor cortex through a minimally-invasive procedure that threads the device up the jugular vein to the brain. Once implanted, it can detect and wirelessly transmit what Synchron calls “motor intent” from the brain, enabling people with severe paralysis to control computers and smartphones with hands-free point-and-click technology.
“The problem of paralysis is much larger than people realize,” Tom Oxley, Synchron’s founder, and CEO said in a statement. “100 million people worldwide have upper limb impairment.”
The investment, a Series C, was led by ARCH Venture Partners and brings the total raised since inception to $145 million, Synchron said. The funding will help the firm speed development of the device and fund a key clinical trial.
An ongoing clinical trial, called COMMAND, is assessing the impact of the device on daily tasks, including texting, emailing, online shopping, and telehealth services. Synchron won Breakthrough Device designation from the Food and Drug Administration in August 2020 and secured an Investigational Device Exemption in July 2021.
Human clinical trials also are underway in Australia and the University of Melbourne took part in the recent fundraising round.
Musk’s firm is currently the target of a federal investigation into the mistreatment of animals on which it has been experimenting with CBIs, Reuters reported earlier this month.
In a recent article in The New York Times on CBIs including Musk’s Neuralink, Cristin Welle, a University of Colorado neuroscientist, noted that device makers will have to “surmount the challenge of operating electronics for years in the soggy milieu of the brain,” and will need to prove that the device “doesn’t generate heat or current that unduly injures the delicate brain tissue.”
NEW YORK TIMES
Published by The New York Times - Christina Jewett and Cade Metz- Dec. 14, 2022
Brain Implants Have Begun to Restore Functions, but Advances Are Slow
But achieving full‑body restoration of movement, as Elon Musk envisions with such devices, is considered far into the future, if at all.
A jumble of cords and two devices the size of soda cans protrude from Austin Beggin’s head when he undergoes testing with a team of researchers studying brain implants that are meant to restore function to those who are paralyzed. Despite the cumbersome equipment, it is also when Mr. Beggin feels the freest. He was paralyzed from the shoulders down after a diving accident eight years ago, and the brain device picks up the electrical surges that his brain generates as he envisions moving his arm. It converts those signals to cuffs on the major nerves in his arm.
They allow him to do things he had not done on his own since the accident, like lift a pretzel to his mouth. “This is like the first time I’ve ever gotten the opportunity or I’ve ever been privileged and blessed enough to think, ‘When I want to open my hand, I open it,’” Mr. Beggin, 30, said. Days like that are always “a special day.” The work at the Cleveland Functional Electrical Stimulation Center represents some of
the most cutting-edge research in the brain-computer interface field, with the team connecting the brain to the arm to restore motion.
It’s a field that Elon Musk wants to advance, announcing in a recent presentation that brain implants from his company Neuralink would someday help restore sight to the blind or return people like Mr. Beggin to “full-body functionality.” Mr. Musk also said the Neuralink devices could allow anyone to use phones and other machines with new levels of
speed and efficiency. Neuroscientists and Mr. Beggin alike see such giant advances as decades away, though. Scientists who have the approval to test such devices in humans are inching toward restoring normal function in typing, speaking, and limited movements.
Researchers caution that the goal is much harder and more dangerous than it may seem. And they warn that Mr. Musk’s goals may never be possible — if it is even worth doing in the first place.
“It is fun to think about science fiction scenarios describing how the world might be,” said Paul Nuyujukian, a professor of bioengineering and neurosurgery at Stanford University who has spent years working on similar technology. “But given where we are right now with the science, it is not clear how those scenarios will be realized.”
The scientists at the Neuralink event on Nov. 30 and those watching online agreed that the engineering that Mr. Musk showed off was an elegant mash-up of some of the best ideas in the decades-old field. Replacing the soda-can-like protrusion from the head would indeed be a significant advance, they acknowledged. Neuralink’s device prototype would eliminate that problem, but only after patients, A biomedical engineer working with Mr. Beggin connected the implant that is attached to the cortex of his brain and skull to equipment for a series of tests.
Daniel Lozada for The New York Times
Elon Musk, a Neuralink co-founder, during an online show-and-tell presentation of the company’s device on Nov. 30. Neuralink undergo robotic surgery to cut a hole in the head slightly larger than a quarter. Then the robot knits 1,024 cobweb-thin electrode tendrils into the gray matter of the brain and rests the puck-like device in the hole. With work so delicate, some researchers in the field worry that one high-profile misstep could erase years of progress. “The communications coming out of Neuralink too often sounds like cowboy activity, right?” said Marcus Gerhardt, chief executive of Blackrock Neurotech, a brain-computer
interface company that could be a Musk rival.
Mr. Gerhardt said the neurosurgeons affiliated with his company “are petrified every day that something terrible could happen there and affect the rest of the space.” Mr. Beggin is one of about three dozen people who have a device called a “Utah array” implanted in the brain for research purposes. The device includes a small grid of electrodes that are dipped barely two millimeters into his brain. That is linked to a portal mounted on his head and, via cables, to another computer. Most of the days Mr. Beggin spends working with the Cleveland research team involved
looking at a moving arm or hand on a computer screen and envisioning himself making the same motion.
That allows researchers to detect the neuron-firing patterns in his brain
that give rise to each movement. Those signals are communicated to a system that manipulates eight nerves in his arm to make it move, said A. Bolu Ajiboye, a professor of biomedical engineering at Case Western Reserve University whose team has been working with patients like Mr. Beggin. The work can be tedious, Mr. Beggin said, but he finds it worthwhile for the days when he can move his hand. His experience builds on work with a prior volunteer, who was also paralyzed in the arms and legs, and managed to lift a forkful of mashed potatoes to his
mouth with the system.
Mr. Beggin did not watch the Neuralink presentation last month. But he said he was dismayed to hear that Mr. Musk raised the notion of “full-body functionality” for people The equipment that allowed Mr. Beggin to send a thought signal through the cortical electrode array to the
nerve cuff electrode in his arm to match what he saw on the screen. Daniel Lozada for The New York Times Mr. Beggin successfully brought a pretzel stick to his mouth for a bite. Daniel Lozada for The New York Times was dismayed to hear that Mr. Musk raised the notion of “full-body functionality” for people who are paralyzed.
It’s an outcome that, given the painstaking work involved in his hand motions, Mr. Beggin expects will take a generation to achieve.
His mother, Shelly Beggin, agrees. “As a parent, I would love to hear that,” Ms. Beggin said. “I would have held onto that hope that he would be able to walk.” Realistically, she said, she’s happy to see her son’s hard-won hand motions. Scientists who work on brain-computer interfaces say that tempering patient expectations is important in a field that has seen stunning progress, but faces daunting challenges.
Academic teams across the nation are working on projects aimed at restoring function to those with disabilities or degenerative diseases. Scientists are working to map the visual center of the brain so points of light can be projected in the mind’s eye to help the blind see shapes and letters. Other teams are working on translating neural electricity into
speech, cursor control, handwriting, and typing applications. Several companies, including Neuralink, are working on fully implantable devices. Paradromics, a start-up in Austin, Texas, is developing a device that sits inside the skull.
Another company, Synchron, based in New York City, is taking a different approach, making an incision in the chest and pushing a tube-shaped device into an artery close to the brain. This avoids the dangers of brain surgery, but the signal it captures from the brain is considerably weaker, according to Tom Oxley, chief executive of Synchron. Mr. Beggin, with his mother, Shelly Beggin, answered a FaceTime call in between physical training sessions.
Daniel Lozada for The New York Times
Despite all the promise in the field, scientists say this technology has very little to offer to the typical consumer, as it is merely approaching the speed and precision of able-bodied control. That seems as if it’s about to change, Dr. Ajiboye said. He compared the field to the computer industry in 1980 when it was on track for a revolution. “I firmly believe that we’re at the same initial ramp curve in terms of understanding brain
mechanisms,” he said. During the Neuralink presentation, a video showed a monkey named Pager reportedly using a prototype implant in its brain to move a cursor across a computer screen.
Mr. Musk’s team also showed off the inner workings of the device, impressing some of the neuroscientists who watched the event.
During the event, Mr. Musk announced that Neuralink was seeking permission from the Food and Drug Administration to test the device in humans, and he guessed that a clinical trial would begin next year.
This would be a notable step forward for the field. Others have tested wireless devices in humans, but Neuralink is investing so heavily in the project that it may come forward quickly with a more powerful device than before.
“They basically sourced a lot of the best ideas out there in the top of the field and paid to bring them together into a new system. And I think that is exciting,” said Cristin Welle, a University of Colorado neuroscientist and former F.D.A. brain-implant lab director and device consultant. “Now whether they can really surmount all of these technical hurdles
to demonstrate that it is in fact safe, it remains to be seen.” It is the F.D.A. that will decide when the trial begins if it grants approval to Neuralink.
The agency will pay close attention to device durability, given the risks and feasibility of repeated brain surgeries, Dr. Welle said.
That means device makers will have to surmount the challenge of operating electronics for years in the soggy milieu of the brain. They will also need to prove that their supercomputing device does not generate heat or current that unduly injures the delicate brain tissue, she said.
Mr. Beggin with A. Bolu Ajiboye, center, a professor of biomedical engineering at Case Western Reserve University, and John Krall, a Ph.D. student studying with Dr. Ajiboye. Daniel Lozada for The New York Times. There are also very real limits to what the device can do. There may be ethical limits too. As Neuralink pursues a human trial, it is fighting complaints over its tests with monkeys.
The company filed papers in a California court this month seeking to block the release of photos of primates it tested from 2017 through 2020. The Physicians Committee for Responsible Medicine, an advocacy group, previously obtained hundreds of pages of veterinary records and filed a complaint with the Agriculture Department, claiming primate test subjects developed infections and were treated carelessly. The Agriculture Department said it could not comment on the group’s complaint, citing
the pending litigation. Neuralink has denied the claims, but they could affect the progress of its technology.
If and when Neuralink begins a human trial, it would be limited to people who have real needs for the technology, most likely those with spinal cord injuries or other forms of paralysis. Although Mr. Musk has said the Neuralink device could be implanted in healthy humans to enhance their abilities, which seems a remote possibility at this stage. He has compared
future uses of the implant to those of another medical device that is marketed for reasons that are not purely disease-curing: Lasik surgery lasers, which are used to improve vision.
“There is an ethics question that needs to be answered, and they have yet to address it,” Dr. Ajiboye said, referring to Mr. Musk and Neuralink.
To Mr. Beggin, implanting such a device in a completely healthy person is a step too far. He would prefer that Mr. Musk and his company focus on people like him who could use this device to restore functions that have been taken away, like shaking someone’s hand or waving to a curious child who approaches his wheelchair. A monkey made a polite request during Mr. Musk’s Neuralink video presentation last month. Neuralink
“Using the technology to allow an able-bodied person to start a car?” he said. “It is a hard thing for me to rationalize.”